Overview

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
Phase:
Phase 3
Details
Lead Sponsor:
Mimetogen Pharmaceuticals USA, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions